Branaplam (LMI070; NVS-SM1) 是一种口服有效和选择性的SMN2拼接调节剂,对 SMN 的EC50为 20 nM。Branaplam 抑制hERG,IC50为 6.3 μM。Branaplam 在严重的脊髓性肌萎缩症 (SMA) 小鼠模型中可提高全长 SMN 蛋白并延长其生存期。
生物活性 | Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally activesurvival motor neuron-2 (SMN2)splicing modulator with anEC50of 20 nM for SMN. Branaplam inhibitshuman-ether-a-go-go-related gene (hERG)with anIC50of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model[1][2]. |
IC50& Target | IC50: 20 nM (SMN)[1] EC50: 6.3 μM (hERG)[2] |
体外研究 (In Vitro) | Branaplam (LMI070; NVS-SM1) treatment induces changes in the levels of 175 genes in human fibroblasts[1].
|
体内研究 (In Vivo) | Branaplam (LMI070; NVS-SM1; 3, 10, 30 mg/kg; oral) produces dose-dependent elevations of SMN2-FL transcript and SMN protein in brain and spinal cord[1]. Branaplam (1 mg/kg of IV; 3 mg/kg of PO) has a CL of 25 mL/min/kg and an AUC of 3.03 μMoh[2]. A single Branaplam (oral; 30 mg/kg) results in significant and durable SMN protein elevation in brain for up to 160 hours in C/+ mice[1]. Branaplam (oral; 0.03, 0.1, 0.3, 1, 3 mg/kg) improves body weight and extendes lifespan in n SMNΔ7 mice[1].
Animal Model: | C/+ SMA mouse model[1] | Dosage: | 3, 10, 30 mg/kg | Administration: | Oral | Result: | Produced dose-dependent elevations of SMN2-FL transcript and SMN protein in brain and spinal cord. |
Animal Model: | Male Sprague-Dawley rat[2] | Dosage: | 1 mg/kg (IV);3 mg/kg (PO) (Pharmacokinetic Analysis) | Administration: | IV or PO | Result: | Had a CL of 25 mL/min/kg and an AUC of 3.03 μMoh. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 5 mg/mL(12.71 mM;ultrasonic and warming and heat to 80℃) 配制储备液 1 mM | 2.5414 mL | 12.7071 mL | 25.4143 mL | 5 mM | 0.5083 mL | 2.5414 mL | 5.0829 mL | 10 mM | 0.2541 mL | 1.2707 mL | 2.5414 mL |
*请根据半岛bd体育手机客户端
在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端
失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 1 mg/mL (2.54 mM); Clear solution
此方案可获得 ≥ 1 mg/mL (2.54 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 0.71 mg/mL (1.80 mM); Clear solution
此方案可获得 ≥ 0.71 mg/mL (1.80 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 7.1 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 0.71 mg/mL (1.80 mM); Clear solution
此方案可获得 ≥ 0.71 mg/mL (1.80 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 7.1 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 4. 请依序添加每种溶剂: 5% DMSO 40%PEG300 5%Tween-80 50% saline Solubility: ≥ 0.57 mg/mL (1.45 mM); Clear solution 5. 请依序添加每种溶剂: 1% DMSO 99% saline Solubility: 0.12 mg/mL (0.30 mM); Suspended solution; Need ultrasonic *以上所有助溶剂都可在本网站选购。
|